G0FB Stock Chart & Stats
€6.55
€0.25(3.82%)
At close: 4:00 PM EDT
€6.55
€0.25(3.82%)
Day’s Range― - ―
52-Week Range€5.95 - €8.40
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€5.76B
Enterprise Value€16.75K
Total Cash (Recent Filing)€529.00M
Total Debt (Recent Filing)€8.52B
Price to Earnings (P/E)14.4
Beta0.47
Next Earnings
Nov 10, 2026EPS Estimate
0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.67
Shares Outstanding261,425,100
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.03
Price to Sales (P/S)0.75
P/FCF Ratio7.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.82
Revenue Forecast (FY)€7.61B
Bulls Say, Bears Say
Bulls Say
Immunoglobulin And Biopharma GrowthStrong immunoglobulin growth demonstrates durable demand for Grifols’ plasma-derived therapies, particularly as XEMBIFY continues gaining traction. Biopharma momentum supports revenue quality, improves product mix, and gives the company a stronger platform for sustained growth across chronic and acute-care markets.
Improving Profitability And Cash GenerationMeaningful improvement in EBITDA, profit, and free cash flow indicates that operational recovery is translating into stronger financial capacity. Higher internally generated cash can support investment in plasma collection, product development, and debt management while reinforcing earnings resilience.
Strategic Plasma Supply ExpansionExpanding ex-U.S. plasma sourcing can improve supply self-sufficiency and strengthen the economics of Grifols’ core medicines business. The Egypt ramp provides a multi-year structural initiative that may reduce reliance on existing collection sources and support future manufacturing scale.
Bears Say
High Financial LeverageThe debt-heavy capital structure remains a material constraint despite some improvement from prior peaks. High leverage can absorb a substantial portion of operating cash flow, reduce flexibility for investment or acquisitions, and leave the company more exposed to refinancing and earnings volatility.
Weak Recent Revenue TrendA sharp trailing revenue decline limits operating leverage and raises questions about the durability of the broader recovery, even as margins improve. Persistent top-line weakness could make it harder to spread fixed costs, reduce leverage, and sustain profit growth across the business.
Diagnostics Transition PressureThe Diagnostics transition creates a structural execution challenge as Grifols adjusts its portfolio, reporting base, and commercial priorities after the joint business dissolution. Repositioning may temporarily weaken comparability and require sustained investment before the platform delivers consistent growth.
Grifols SA News
G0FB FAQ
What was Grifols SA’s price range in the past 12 months?
Grifols SA lowest stock price was €5.95 and its highest was €8.40 in the past 12 months.
What is Grifols SA’s market cap?
Grifols SA’s market cap is €5.76B.
When is Grifols SA’s upcoming earnings report date?
Grifols SA’s upcoming earnings report date is Nov 10, 2026 which is in 54 days.
How were Grifols SA’s earnings last quarter?
Grifols SA released its earnings results on Jul 28, 2026. The company reported €0.226 earnings per share for the quarter, missing the consensus estimate of €0.227 by >-€0.001.
Is Grifols SA overvalued?
According to Wall Street analysts Grifols SA’s price is currently Overvalued.
Does Grifols SA pay dividends?
Grifols SA does not currently pay dividends.
What is Grifols SA’s EPS estimate?
Grifols SA’s EPS estimate is 0.26.
How many shares outstanding does Grifols SA have?
Grifols SA has 261,425,100 shares outstanding.
What happened to Grifols SA’s price movement after its last earnings report?
Grifols SA reported an EPS of €0.226 in its last earnings report, missing expectations of €0.227. Following the earnings report the stock price went down -0.758%.
Which hedge fund is a major shareholder of Grifols SA?
Currently, no hedge funds are holding shares in DE:G0FB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Grifols SA Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.72%
12-Months-Change
Fundamentals
Return on Equity
3.75%
Trailing 12-Months
Asset Growth
-1.01%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Grifols SA
Grifols, S.A., a company founded in 1940 and headquartered in Barcelona, Spain, specializes in the development, manufacture, and distribution of therapeutic products, with a primary focus on those derived from human plasma. Its operations are organized into several divisions. The Bioscience division is dedicated to researching, producing, and marketing plasma-derived medicines, such as immunoglobulins, alpha-1 antitrypsin, albumin, and clotting factors, along with other innovative treatments for chronic, rare, prevalent, and life-threatening conditions. The Hospital division provides non-biological pharmaceuticals, medical supplies, clinical nutrition solutions, intravenous therapies, and medical devices. The Diagnostic division develops, manufactures, and commercializes diagnostic products that span the entire healthcare continuum, from prevention and screening to diagnosis, prognosis, and monitoring of diseases and treatments, catering to professional healthcare providers. The Bio Supplies division offers essential biological materials for life-science research, clinical trials, and the manufacturing of pharmaceutical and diagnostic products. These diverse offerings enable healthcare professionals to diagnose and treat patients suffering from conditions like hemophilia, immune deficiencies, and infectious diseases. Grifols serves a wide array of clients, including public and private healthcare organizations, wholesalers, distributors, group purchasing organizations, blood banks, hospitals, and national health systems. The company also maintains a technology collaboration agreement with Mondragon.
G0FB Company Deck
G0FB Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call conveys a constructive and confident tone: the company reported modest top-line growth with strong momentum in Biopharma—notably IG and subcutaneous IG—improving adjusted EBITDA, higher group profit, and better free cash flow. Strategic initiatives (Egypt plasma ramp, diagnostics platform development, Biopharma reorganization, Biotest turnaround) and debt refinancing strengthen the long‑term profile. Near-term headwinds include albumin pricing effects in China, one‑off costs from donor center closures, and transitional diagnostics comparability, but management provided clear mitigation plans and timing for expected benefits.View all DE:G0FB earnings summaries